Evaluation of the Potential Risk of Porcine Endogenous Retrovirus (PERV) Infection in Nude Mice

Bae, Eun Hye; Jung, Yong-Tae

doi:10.4014/jmb.1012.12013

Cited by 1 publication

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from animal studies , and human xenotransplantation clinical trials and reports , showed lack of viral replication and transmission of PERV in vivo . However, the possibility of cross‐species transmission of PERV could not be ruled out due to tangible in vitro data from our laboratory and others showing that exposure of human cells to pig‐derived biological materials (i.e., plasma, blood, endothelial cells) results in PERV transmission in vitro.…”

Section: Introductionmentioning

confidence: 99%

Susceptibility of porcine endogenous retrovirus to anti‐retroviral inhibitors

Argaw

Colon-Moran

Wilson

2016

Xenotransplantation

View full text Add to dashboard Cite

Background Porcine endogenous retrovirus (PERV) is an endogenous retrovirus that poses a risk of iatrogenic transmission in the context of pig-to-human xenotransplantation. The lack of a means to control PERV infection in the context of pig-to-human xenotransplantation is a major concern in the field. In this study, we set out to evaluate the ability of currently licensed anti-HIV drugs, and other types of anti-retroviral compounds, to inhibit PERV infection in vitro. Methods We used target cells stably expressing one of the known PERV viral receptors, an infectious molecular clone, PERV-A 14/220, and at least one drug from each class of anti-retroviral inhibitors as well as off-label drugs shown to have anti-viral activities. The susceptibility of PERV-A 14/220 LacZ to the anti-retroviral drugs was determined from infected cells by histochemical staining. Results We extend the results of previous studies by showing that, in addition to raltegravir, dolutegravir is found to have a potent inhibitory activity against PERV replication (IC50 8.634 ±0.336 and IC50 3.06 ± 0.844 nm, respectively). The anti-HIV drug zidovudine (AZT) showed considerable anti-PERV activity with IC50 of 1.923 ±0.691 μm as well. Conclusions The study results indicate that some of the licensed antiretroviral drugs may be useful for controlling PERV infection. However, the efficacy at nanomolar concentrations put forward integrase inhibitors as a drug that has the potential to be useful in the event that xenotransplantation recipients have evidence of PERV transmission and replication.

show abstract

Section: Introductionmentioning

confidence: 99%